Notably, FDFT1 knockdown was still effective at 22 weeks and significantly relieved the tumor burden, as evidenced by the decreases in tumor number, liver/body ratio, and tumor maximum diameter in the FDFT1‐knockdown group (Figure 3F–K). The gene discussed is FDFT1; the disease is neoplasm.